Применение бета-адреноблокаторов у пациентов с артериальной гипертонией

В настоящем консенсусе экспертов Российского медицинского общества по артериальной гипертонии представлена роль бета-адреноблокаторов в лечении пациентов с артериальной гипертонией в сочетании как с сердечно-сосудистыми заболеваниями, так и с другой сопутствующей патологией, которая может встречаться у пациентов с АГ чаще, чем у людей с нормальным уровнем артериального давления.

1. Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967. https://doi.org/10.1016/S0140-6736(15)01225-8

2. Чазова И.Е., Чихладзе Н.М., Блинова Н.В., и соавт. Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Кардиологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024). Системные гипертензии. 25 декабря 2024;21(4):5-109. https://doi.org/10.38109/2075-082X-2024-4-5-109

3. Wei J., Galaviz K.I., Kowalski A.J., et al. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Metaanalysis. JAMA. Netw Open 2020;3:e1921618. https://doi.org/10.1001/jamanetworkopen.2019.21618

4. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614

5. Mancia G., Kreutz R., Brunström M., et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa). J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621

6. Кобалава Ж.Д., Конради А.О., Недогода С.В., и соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6117. https://doi.org/10.15829/1560-4071-2024-6117

7. do Vale G.T., Ceron C.S., Gonzaga N.A., Simplicio J.A., Padovan J.C. Three generations of b-blockers: history, class differences and clinical applicability. Current hypertension reviews 2019;15:22-31. https://doi.org/10.2174/1573402114666180918102735

8. Mancia G., Kjeldsen S.E., Kreutz R., et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/ European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153-1166. https://doi.org/10.1161/HYPERTENSIONaHa.122.19020

9. Razo C., Welgan C.A., Johnson C.O., et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med. 2022;28(10):2056-2065. https://doi.org/10.1038/s41591-022-01974-1

10. Lewington S., Clarke R., Qizilbash N., et al. Prospective Studies Collaboration. age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003 Mar 22;361(9362):1060]. Lancet. 2002;360(9349):1903-1913. https://doi.org/10.1016/s0140-6736(02)11911-8

11. Vidal-Petiot E., Ford I., Greenlaw N., et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142-2152. https://doi.org/10.1016/S0140-6736(16)31326-5

12. Manolis A.J., Boden W.E., Collins P., et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021;92:40-47. https://doi.org/10.1016/j.ejim.2021.08.003

13. Hwang D., Lee J.M., Kim H.K., et al. Prognostic Impact of ?-Blocker Dose after acute Myocardial Infarction. Circ J. 2019;83(2):410-417. https://doi.org/10.1253/circj.CJ-18-0662

14. Kolloch R., Legler U.F., Champion a, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327-1334. https://doi.org/10.1093/eurheartj/ehn123

15. Барбараш О.Л., Карпов Ю.А., Панов А.В., и соавт. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. https://doi.org/10.15829/1560-4071-2024-6110

16. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-2160. https://doi.org/10.1097/HJH.0000000000001547

17. Haider A.W., Larson M.G., franklin S.S., Levy D.; Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham Heart Study. Ann Intern Med. 2003;138(1):10-16. https://doi.org/10.7326/0003-4819-138-1-200301070-00006

18. McMurray J.J., Packer M., Desai A.S., et al. angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077

19. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JaMa. 1996;275(20):1557-62. PMID: 8622246

20. Ситникова М.Ю., Лясникова Е.А., Юрченко А.В. и соавт. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология 2015;10:5-13. https://doi.org/10.18565/cardio.2015.10.5-13

21. Терещенко С.Н., Жиров И.В., Ускач Т.М., и соавт. Клинические рекомендации Евразийской Ассоциации Кардиологов (ЕАК)/ Национального общества по изучению сердечной недостаточности и заболеваний миокарда (НОИСН) по диагностике и лечению хронической сердечной недостаточности (2024). Евразийский кардиологический журнал. Май 2024;(2):6-76. https://doi.org/10.38109/2225-1685-2024-2-6-76

22. Gattis W.A., O’Connor C.M., Leimberger J.D., et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol 2003;91:169-74. https://doi.org/10.1016/S0002-9149(02)03104-1

23. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385-90. https://doi.org/10.1016/S0140-6736(00)04560-8

24. Cleland J.G.F., Bunting K.V., Flather M.D., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. https://doi.org/10.1093/eurheartj/ehx564

25. Чазова И.Е., Голицын С.П., Жернакова Ю.В. и др. Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий. Системные гипертензии. 2021;18(3):105-128. https://doi.org/10.26442/2075082X.2021.3.201077

26. Попов С.В., Давтян К.В., Шубик Ю.В. и др. Наджелудочковые тахикардии. Клинические рекомендации 2025. Российский кардиологический журнал. 2025; 30(7):6448. EDN: ZLGSCN https://doi.org/10.15829/1560-4071-2025-6448

27. Van Gelder I.C., Rienstra M., Bunting K.V. et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176

28. Grandi E., Ripplinger C.M. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res. 2019 Aug;146:104274. Epub 2019 May 14. PMID: 31100336; PMCID: PMC6679787. https://doi.org/10.1016/j.phrs.2019.104274

29. Olshansky B., Rosenfeld L.E., Warner A.L. et al. AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8. PMID: 15063430. https://doi.org/10.1016/j.jacc.2003.11.032

30. Piccini, J. P., Hranitzky, P. M., Kilaru, R. et al. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan in Acute myocardial iNfarcTion trial [VALIANT] Registry). Am. J. Cardiol. 2008: 102, 1427-1432. https://doi.org/10.1016/j.amjcard.2008.07.033

31. Zeitler E.P., Al-Khatib S.M., Friedman D.J., et al. Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. J Cardiovasc Electrophysiol. 2017 Nov;28(11):1345-1351. Epub 2017 Aug 23. PMID: 28744959; PMCID: PMC5693305. https://doi.org/10.1111/jce.13307

32. Wołowiec Ł., Grześk G., Osiak J. et al. Beta-blockers in cardiac arrhythmias-Clinical pharmacologist's point of view. Front Pharmacol. 2023 Jan 9;13:1043714. PMID: 36699057; PMCID: PMC9868422. https://doi.org/10.3389/fphar.2022.1043714

33. Muresan L., Cismaru G., Muresan C. et al. Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review. Ann Pharm Fr. 2022 Sep;80(5):617-634. Epub 2022 Jan 31. PMID: 35093388. https://doi.org/10.1016/j.pharma.2022.01.007

34. Olshansky B., Sullivan R.M. Inappropriate sinus tachycardia. Europace. 2019 Feb 1;21(2):194-207. PMID: 29931244. https://doi.org/10.1093/europace/euy128

35. Brugada J., Katritsis D.G., Arbelo E., et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720. https://doi.org/10.1093/eurheartj/ehz467

36. Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias. A multicentre study. Ann Clin Res. 1981;13 Suppl 30:68-72. PMID: 7027895

37. Arsura E., Lefkin A.S., Scher D.L., et al. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med. 1988 Oct;85(4):519-24. https://doi.org/10.1016/s0002-9343(88)80088-3. Erratum in: Am J Med 1989 Jan;86(1):142. PMID: 3052051. https://doi.org/10.1016/s0002-9343(88)80088-3

38. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354(9192):1751-6. https://doi.org/10.1016/S0140-6736(99)10327-1

39. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-6. https://doi.org/10.1016/S0140-6736(98)05012-0

40. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3

41. Тарзиманова А.И., Исаева А.Ю. Новые возможности антиаритмической терапии фибрилляции предсердий. Терапевтический архив. 2024;96(2):181-185. https://doi.org/10.26442/00403660.2024.02.202585

42. Mulder B.A., Van Veldhuisen D.J., Crijns H.J. et al. RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014 Sep;11(9):1543-50. Epub 2014 Jun 9. PMID: 24924587. https://doi.org/10.1016/j.hrthm.2014.06.007

43. Kotecha D., Bunting K.V., Gill S.K. et al. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on PatientReported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020 Dec 22;324(24):2497-2508. PMID: 33351042; PMCID: PMC7756234. https://doi.org/10.1001/jama.2020.23138

44. Karwath A., Bunting K.V., Gill S.K. et al. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis. Lancet. 2021 Oct 16;398(10309):1427-1435. Epub 2021 Aug 30. PMID: 34474011; PMCID: PMC8542730. https://doi.org/10.1016/S0140-6736(21)01638-X

45. Crystal E., Garfinkle M.S., Connolly S.S., et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003611. https://doi.org/10.1002/14651858.cd003611.pub2

46. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126. PMID: 36017572. https://doi.org/10.1093/eurheartj/ehac262

47. Schupp T., Behnes M., Weiß C. et al. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia. Cardiovasc Drugs Ther. 2018 Aug;32(4):353-363. PMID: 30074111. https://doi.org/10.1007/s10557-018-6812-z

48. Жернакова Ю.В., Азимова М.О., Железнова Е.А., и др. Оценка распространенности поражения органов-мишеней на различных этапах кардиометаболического континуума. По данным исследования ЭССЕ РФ. Системные гипертензии. 2022;19(3):31-39. https://doi.org/10.38109/2075-082X-2022-3-31-39

49. Жернакова Ю.В., Чазова И.Е., Ощепкова Е.В. и др. Распространенность сахарного диабета в популя ции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ. Системные гипертензии. 2018;15(1):56-62. https://doi.org/10.26442/2075-082X_15.1.56-62

50. Chen S., Tian P., Estau D., Li Z. Effects of β-blockers on all-cause mortality in patients with diabetes and coronary heart disease: A systematic review and meta-analysis. Front Cell Dev Biol. 2023;11:1076107. Published 2023 Jan 27. https://doi.org/10.3389/fcell.2023.1076107

51. Hirst J.A., Farmer A.J., Feakins B.G., Aronson J.K., Stevens R. Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus – a systematic review and metaanalysis. Br J Clin Pharmacol. 2015;79(5):733-743. https://doi.org/10.1111/bcp.12543

52. Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486

53. Чазова И.Е., Шестакова М.В., Жернакова Ю.В., и соавт. Евразийские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с диабетом и предиабетом (2021). Евразийский Кардиологический Журнал. 2021;(2):6-61. https://doi.org/10.38109/2225-1685-2021-2-6-61

54. Carella A.M., Antonucci G., Conte M., et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr. Diabetes Rev. 2010; 6 (4): 215-221. https://doi.org/10.2174/157339910791658844

55. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227-2236. https://doi.org/10.1001/jama.292.18.2227

56. Schmidt A.C., Graf C., Brixius K., Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27(12):841-849. https://doi.org/10.2165/00044011-200727120-00006

57. Чазова И.Е., Невзорова В.А., Амбатьелло Л.Г. и др. Клинические рекомендации по диагностике и лечению пациентов с артериальной гипертонией и хронической обструктивной болезнью легких. Системные гипертензии. 2020;17(3):7-34 https://doi.org/10.26442/2075082X.2020.3.200294

58. Климова АА, Амбатьелло ЛГ, Смолякова ЕВ и др. Частота выявления сочетанной бронхообструктивной патологии у пациентов с артериальной гипертонией, поступающих в специализированный кардиологический стационар. Системные гипертензии. 2023;20(1):35-43 https://doi.org/10.38109/2075-082X-2023-1-35-43

59. Dhungel S., Paudel B., Shah S. Study of prevalence of hypertension in Chronic Obstructive Pulmonary Disease patients admitted at Nepal Medical College and Teaching Hospital. Nepal Medical College Journal. 2005;7(2):90‑92. PMID: 16519071

60. McGavin C.R., Williams I.P. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 1978;72(4):327-32. PMID: 365214

61. Brooks Т.W., Creekmore F.M., Young D.C. at al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy. 2007;27(5):684-90. https://doi.org/10.1592/phco.27.5.684

62. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD003566. Published 2005 Oct 19. https://doi.org/10.1002/14651858.CD003566.pub2

63. Ni Y., Shi G., Wan H. Use of Cardioselective b-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. J Int Med Res 2012;40(6):2051-65. https://doi.org/10.1177/030006051204000602

64. Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021 Mar 1;27(2):125-131. https://doi.org/10.1097/MCP.0000000000000748

65. Lin R., Peng H., Nguyen L.P., et al. Changes in beta 2-adrenoreceptor and other signaling proteins produced by chronic administration of “beta blockers” in a murine asthma model. Pulm Pharmacol Ther 2008;21:115-24. https://doi.org/10.1016/j.pupt.2007.06.003

66. Short P.M., Lipworth S.I., Elder D.H., Schembri S., Lipworth B.J. Effect of b-blockers in treatment of chronic obstructive pulmonary disease: a retro spective cohort study. BMJ 2011;342:d2549. https://doi.org/10.1136/bmj.d2549

67. Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3(4):329-334. https://doi.org/10.1177/1753944709339968

68. Stefan M.S., Rothberg M.B., Priya A., Pekow P.S., Au D.H., Lindenauer P.K. Association between b-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-84. https://doi.org/10.1136/thoraxjnl-2012-201945

69. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. https://doi.org/10.1016/j.amjmed.2008.09.038

70. Lammers J.W., Folgering H.T., van Herwaarden C.L. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986:8 Suppl 11:S69-73. https://doi.org/10.1097/00005344-198511001-00012

71. Lawrence D.S., Sahay J.N., Chatterjee S.S., Cruickshank J.M. Asthma and beta-blockers. Eur J Clin Pharmacol 1982;22(6):501-9. https://doi.org/10.1007/BF00609622

72. Huang K., Tseng P., Wu Y. at al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021 Jan 11;11(1):452. https://doi.org/10.1038/s41598-020-79837-3

73. Marko M., Pawliczak R. An updated insight into the effect of β-adrenergic receptor antagonists (β-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis. Front Physiol. 2025 Jul 25;16:1582740. https://doi.org/10.3389/fphys.2025.1582740

74. Itoga N.K., Tawfik D.S., Lee C.K., Maruyama S., Leeper N.J., Chang T.I. Association of Blood Pressure Measurements With Peripheral Artery Disease Events. Circulation. 2018;138(17):1805-1814. https://doi.org/10.1161/CIRCULATIONAHA.118.033348

75. Thomas Manapurathe D., Krishna S.M., Dewdney B., Moxon J.V., Biros E., Golledge J. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials. PLoS One. 2017;12(6):e0178713. Published 2017 Jun 2. https://doi.org/10.1371/journal.pone.0178713

76. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;2013(9):CD005508. Published 2013 Sep 11. https://doi.org/10.1002/14651858.CD005508.pub3

77. Paravastu S.C., Mendonca D.A., da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(1):66-70. https://doi.org/10.1016/j.ejvs.2009.02.019

78. Espinola-Klein C., Weisser G., Jagodzinski A., et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148-154. https://doi.org/10.1161/HYPERTENSIONAHA.110.169169

79. Rabkin R., Stables D.P., Levin N.W., Suzman M.M. The prophylactic value of propranolol in angina pectoris. Am J Cardiol. 1966;18(3):370-383. https://doi.org/10.1016/0002-9149(66)90056-7

80. Rubio-Beltrán E., Schoon R.M., van den Berg J., et al. Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol. 2022;9(9):1405-1416. https://doi.org/10.1002/acn3.51640

81. Shields K.G., Goadsby P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128(Pt 1):86-97. https://doi.org/10.1093/brain/awh298

82. Ayata C., Jin H., Kudo C., Dalkara T., Moskowitz M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59(4):652-661. https://doi.org/10.1002/ana.20778

83. Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785. Published 2019 Mar 20. https://doi.org/10.1371/journal.pone.0212785

84. Fumagalli C., Maurizi N., Marchionni N., Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:104587. https://doi.org/10.1016/j.phrs.2019.104587

85. Adham N., Ellerbrock B., Hartig P., Weinshank R.L., Branchek T. Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system. Mol Pharmacol. 1993;43(3):427-433. PMID: 8095694.

86. Versijpt J., Deligianni C., Hussain M., et al. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention – part 4: propranolol. J Headache Pain. 2024;25(1):119. Published 2024 Jul 24. https://doi.org/10.1186/s10194-024-01826-y

87. Клинические рекомендации Минздрава России. Мигрень, 2024 г. https://cr.minzdrav.gov.ru/preview-cr/295_4

88. Landgren A.J., Dehlin M., Jacobsson L., Bergsten U., Klingberg E. Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open. 2021;7(2):e001568. https://doi.org/10.1136/rmdopen-2021-001568

89. Mehta N.N., Yu Y., Pinnelas R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1-775.e7756. https://doi.org/10.1016/j.amjmed.2011.03.028

90. Hu X., Li J., Fu M., Zhao X., Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. Published 2021 Nov 26. https://doi.org/10.1038/s41392-021-00791-1

91. Song G., Kim J.Y., Yoon H.Y., Yee J., Gwak H.S. A systematic review and meta-analysis of angiotensinconverting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021;11(1):10037. Published 2021 May 11. https://doi.org/10.1038/s41598-021-89490-z

92. Ganeva M., Tsokeva Z., Gancheva T., Hristakieva E., Tsoneva V., Manolova I. Serum concentrations of 25-OH vitamin D and the pro-inflammatory interleukins IL-17, IL-23, and IL-18 in patients with plaque psoriasis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024;168(2):124-131. https://doi.org/10.5507/bp.2023.043

93. Azzouz B., De Guizelin A., Lambert A., Fresse A., Morel A., Trenque T. Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022;88(8):3813-3818. https://doi.org/10.1111/bcp.15330

94. Dodulík J., Dodulíková L., Plášek J., Ramík Z., Vrtal J., Václavík J. Pharmacotherapy of arterial hypertension in patients with psoriasis. J Hypertens. 2025;43(4):568-576. https://doi.org/10.1097/HJH.0000000000003982

95. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270(1):83-90. PMID: 8510302.

96. Korneyev I.A., Alexeeva T.A., Al-Shukri S.H., et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74-79. https://doi.org/10.1038/ijir.2016.8

97. Doumas M., Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich). 2006;8(4):269-274. https://doi.org/10.1111/j.1524-6175.2006.04708.x

98. Doumas M., Tsiodras S., Tsakiris A., et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24(12):2387-2392. https://doi.org/10.1097/01.hjh.0000251898.40002.5b

99. Клинические рекомендации «Эректильная дисфункция», 2025. Одобрено МЗ РФ, Российское общество урологов.

100. Farmakis I.T., Pyrgidis N., Doundoulakis I., Mykoniatis I., Akrivos E., Giannakoulas G. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovasc Drugs Ther. 2022;36(5):903-914. https://doi.org/10.1007/s10557-021-07197-9

101. Silvestri A., Galetta P., Cerquetani E., et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J. 2003;24(21):1928-1932. https://doi.org/10.1016/j.ehj.2003.08.016

102. Nehra A., Jackson G., Miner M., et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://doi.org/10.1016/j.mayocp.2012.06.015

103. Viigimaa M., Vlachopoulos C., Doumas M., et al. Update of the position paper on arterial hypertension and erectile dysfunction. J Hypertens. 2020;38(7):1220-1234. https://doi.org/10.1097/HJH.0000000000002382

104. Fogari R., Preti P., Zoppi A., et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004;17(1):77-81. https://doi.org/10.1016/j.amjhyper.2003.08.016

105. Doumas M., Douma S. The effect of antihypertensive drugs on erectile function: a proposed management algorithm. J Clin Hypertens (Greenwich). 2006;8(5):359-364. https://doi.org/10.1111/j.1524-6175.2005.05285.x

106. Алексеева Т.А., Литвин А.Ю., Елфимова Е.М. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и эректильная дисфункция. Системные гипертензии. 2021;18(2):69-79. https://doi.org/10.26442/2075082X.2021.2.200836

107. Julie De Backer, Kristina H Haugaa, Nina Eide Hasselberg et al. ESC Scientific Document Group, 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC) Endorsed by the European Society of Gynecology (ESG). Eur Heart J . 2025 Aug 29:ehaf193. https://doi.org/10.1093/eurheartj/ehaf193

108. Halpern D.G., Weinberg C.R., Pinnelas R., Mehta-Lee S., Economy K.E., Valente A.M. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-476. https://doi.org/10.1016/j.jacc.2018.10.075

109. Bellos I., Pergialiotis V., Papapanagiotou A., Loutradis D., Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. Am J Obstet Gynecol. 2020;223(4):525-537. https://doi.org/10.1016/j.ajog.2020.03.016

110. Lydakis C., Lip G.Y., Beevers M., Beevers D.G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541-547. https://doi.org/10.1016/s0895-7061(99)00031-x

111. Tita A.T., Szychowski J.M., Boggess K., et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. https://doi.org/10.1056/NEJMoa2201295

112. Malhamé I., Nerenberg K., McLaughlin K., Grandi S.M., Daskalopoulou S.S., Metcalfe A. Hypertensive Disorders and Cardiovascular Severe Maternal Morbidity in the US, 2015-2019. JAMA Netw Open. 2024;7(10):e2436478. Published 2024 Oct 1. https://doi.org/10.1001/jamanetworkopen.2024.36478

113. Villar J., Carroli G., Wojdyla D., et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921-931. https://doi.org/10.1016/j.ajog.2005.10.813

114. Brown M.C., Best K.E., Pearce M.S., Waugh J., Robson S.C., Bell R. Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol. 2013;28(1):1-19. https://doi.org/10.1007/s10654-013-9762-6

115. Cífková R., Johnson M.R., Kahan T., et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):384-393. https://doi.org/10.1093/ehjcvp/pvz082

116. Drugs and Lactation Database (LactMed). https:/www.ncbi.nlm.nih.gov/books/NBK501922/ (29 January 2025, date last accessed).

117. Ryu R.J., Eyal S., Easterling T.R., et al. Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol. 2016;56(5):581-589. https://doi.org/10.1002/jcph.631